Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2755 Target Snapshot

Glutathione reductase, mitochondrial · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
301Compounds
104Assays
5Approved Drugs
269.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Glutathione reductase, mitochondrial shows approved-linked disease relevance led by anaplastic astrocytoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P00390. Start with anaplastic astrocytoma, then reuse UniProt P00390 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with anaplastic astrocytoma, then reuse UniProt P00390 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
anaplastic astrocytoma

Glutathione reductase, mitochondrial shows approved-linked disease relevance led by anaplastic astrocytoma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with anaplastic astrocytoma because it currently carries approved-linked support. Linked drugs include CARMUSTINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glutathione reductase, mitochondrial as ChEMBL target CHEMBL2755, mapped to UniProt P00390. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glutathione reductase, mitochondrial
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2755
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P00390
Glutathione reductase, mitochondrial
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Glutathione reductase, mitochondrial is the right protein anchor across sources, using UniProt P00390 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why anaplastic astrocytoma is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameGlutathione reductase, mitochondrial
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP00390
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGlutathione reductase, mitochondrial
UniProt AccessionP00390
Component TypeProtein
Sequence Length522 aa

Glutathione reductase, mitochondrial

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Glutathione reductase, mitochondrial, mapped to UniProt P00390. Sequence length is 522 aa.

Mapped IDP00390
Review nameGlutathione reductase, mitochondrial
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Glutathione reductase, mitochondrial shows approved-linked disease relevance led by anaplastic astrocytoma. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
anaplastic astrocytoma
1 linked drug · 1 direct · 1 efficacy
Linked drugCARMUSTINE
Approved-linked Approved
astrocytoma
1 linked drug · 1 direct · 1 efficacy
Linked drugCARMUSTINE
Approved-linked Approved
classic Hodgkin lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugCARMUSTINE
Approved-linked Approved
ependymoma
1 linked drug · 1 direct · 1 efficacy
Linked drugCARMUSTINE
Approved-linked Approved
glioblastoma multiforme
1 linked drug · 1 direct · 1 efficacy
Linked drugCARMUSTINE
Approved-linked Approved
glioma
1 linked drug · 1 direct · 1 efficacy
Linked drugCARMUSTINE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with anaplastic astrocytoma because it currently carries approved-linked support. Linked drugs include CARMUSTINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseanaplastic astrocytoma
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
2
Phase III
4
Phase II
Assay Mix

Activity Type Distribution

IC50240.0
KI27.0
KD2.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL120147 8.39 IC50 4.1 Preclinical
CHEMBL1824793 6.68 Ki 211.0 Preclinical
CHEMBL1824793 6.46 IC50 344.0 Preclinical
CHEMBL5425052 6.23 IC50 590.0 Preclinical
CHEMBL135536 6.12 IC50 750.0 Preclinical
CHEMBL39137 6.0 IC50 1000.0 Preclinical
CHEMBL287849 6.0 IC50 1000.0 Preclinical
CHEMBL39225 6.0 IC50 1000.0 Preclinical
CHEMBL135504 6.0 IC50 1000.0 Preclinical
CHEMBL135287 5.75 IC50 1800.0 Preclinical
Distribution

pChEMBL Value Distribution

24
5.0
11
5.5
7
6.0
1
6.5
0
7.0
0
7.5
1
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

114
Total Assays
88
Tested Compounds
3
Assay Types
Binding — 108 assays, 88 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 97 88 5.0
cell-based format 10 0 —
mitochondrion format 1 0 —
Functional — 5 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 5 0 —
Toxicity — 1 assays, 5 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 5 5.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine